A similar level of survival was obtained with combination Doxil at 2.5 mg/kg with IL-18 at 100 μg (Figure 4) suggesting that the efficacy of Doxil therapy for ovarian cancer can be improved by the addition of IL-18. Here, IL18 is linked to ovarian carcinoma.